Friday, 20 Oct 2017

You are here

Upadacitinib Effective in Rheumatoid Arthritis

AbbVie released the preliminary results of a rheumatoid arthritis trial wherein its Jak inhibitor, upadacitinib, was tested against placebo, and shown to be superior in established RA patients who have failed prior DMARD therapy.

Two doses of upadacitinib (15 mg and 30 mg) were studied against placebo for 12 weeks and shown to produced significantly greater ACR20, ACR50, and  ACR70 scores (64%, 66%, 20%, respectively).

Clinical remission was seen in 31%, 28% and 10%, of those taking 15 mg, 30 mg and placebo (p<0.001). Low disease activity was achieved in 48% of patients on upadacitinib, compared to 17% of patients on placebo).

No new or surprising safety signals were reported.

Updacitinib is being considered for other indications, including psoriatic arthritis, Crohn's disease, ulcerative colitis and atopic dermatitis.

 

 

 

 

 

 

Disclosures: 
The author has received compensation as an advisor or consultant on this subject

Add new comment

More Like This

Patterns of Biologic Use During Autoimmune Pregnancy

While it is highly desirable to avoid medications during conception and pregnancy, statistics show that >90% of women take at least one drug during pregnancy and nearly half will take 3 or more medications during pregnancy.

Sirukumab Turned Down by FDA

On Friday the U.S. Food and Drug Administration announced that will not approve Johnson & Johnson’s rheumatoid arthritis drug sirukumab, stating further data and study would be needed to establish its safety. 

Rituximab Efficacy in IgG4 Related Disease

PLOS reports  greater than 90% efficacy when rituximab (RTX) is used to treat patients with IgG4-related disease (IgG4-RD). 

Jak Inhibition May Ameliorate Pruritus

Interleukin-4 has been shown to activate sensory neurons involved in pruritus, and that inhibition of IL-4 with Jak inhibition significantly alleviates itching.

Biologic Use in Adult-Onset Still's Disease

 Adult-onset Still's disease (AOSD) is the adult continum of systemic-onset juvenile idiopathic arthritis (SoJIA). Treatment of this febrile polyarticular systemic disorder can be complex, but has been relieved by several specific biologic therapies.